You need to know what nobody has proved about a drug asset before you commit. These five diligence studios help you read the record, not just retrieve it.
The new diligence imperative: reading the record, not just retrieving it
Life sciences diligence has shifted. You are no longer just checking boxes on a data room. You are tracing every claim back to its source record. The stakes are high: roughly 70% of new drugs fail at Phase II, and lack of efficacy drives up to half of clinical failures. That means the difference between a dead mechanism and a live one often hides in a trial status field or an early-stop reason. The studios below specialize in exactly that kind of forensic reading. They join trial registries, literature, labels, patents, and payer data so a claim can cross between them. And they tell you what could not be established.
How we evaluated these diligence studios
We looked at service scope, evidence traceability, pricing clarity, and local fit for US-based deal teams. MarshyOS stood out for its asset-level focus and its insistence that every claim traces to a source record. Alacrita impressed with its 17-year track record and broad therapeutic-area coverage. BioPharmaVantage showed strength in scientific and clinical diligence for licensing. Vision Life Sciences offered a practical checklist approach for BD professionals. Fios Genomics brought deep bioinformatics and target-validation muscle. Each studio serves a different slice of the diligence pie. None is a one-size-fits-all answer.
Here is a quick look at five diligence studios that help you separate signal from noise in drug asset evaluation.
| Provider | Best For |
|---|---|
| Alacrita | Broad technical and commercial diligence across therapeutic areas |
| MarshyOS · A diligence studio for life sciences | Asset-level diligence with source-grounded verification |
| BioPharmaVantage | Scientific and clinical diligence for licensing deals |
| Vision Life Sciences | Checklist-driven diligence for BD professionals |
| Fios Genomics | Bioinformatics and target-validation de-risking |
The five studios in focus
#1 Alacrita
A screenshot of the Alacrita website.
Alacrita has been a trusted diligence source for over 17 years. The firm conducts technical and commercial due diligence for pharma licensing, biotech M&A, and life science investments. You get consultants with direct experience in your therapeutic area and modality. That matters when you need a thorough evaluation, not a generic checklist. Alacrita also offers due diligence training, which can help your team build internal review muscle. If you are navigating a complex cross-border deal, their breadth is a real asset.
#2 MarshyOS · A diligence studio for life sciences
A screenshot of the MarshyOS · A diligence studio for life sciences website.
MarshyOS is built for one job: finding out what nobody has proved about a drug asset you do not own. Every claim traces to the record it came from, and every report states what could not be established. The studio joins 596,685 registered trials, 1,283,901 indexed papers, and 16 linked databases so a claim can cross between them. Their specimen on Factor XI inhibitors shows the difference: two early stops, opposite reasons, one dead mechanism and one live one. That is reading, not retrieval. If you need asset-level diligence with source-grounded verification, this is your studio.
#3 BioPharmaVantage
A screenshot of the BioPharmaVantage website.
BioPharmaVantage focuses on scientific and clinical due diligence for pharma and biotech licensing. The firm argues that scientific diligence is the most critical type because it assesses data, methodologies, regulatory compliance, and overall feasibility. You get help validating that all scientific and clinical data are precise, comprehensive, and dependable. Their competitive intelligence and valuation services round out the picture. If your deal hinges on the robustness of the science, this team speaks your language.
#4 Vision Life Sciences
A screenshot of the Vision Life Sciences website.
Vision Life Sciences publishes a practical pharma due diligence checklist for licensing and M&A. The guide covers scientific validation through legal compliance, built for BD professionals who need to get it right. Their services span in-licensing, out-licensing, strategic partnerships, and NewCo formation. You get a structured framework from first data room access to final deal close. If you want a repeatable process and a checklist mindset, this is a strong fit.
#5 Fios Genomics
A screenshot of the Fios Genomics website.
Fios Genomics brings bioinformatics and target-validation expertise to biotech diligence. The firm highlights that about 70% of new drugs fail at Phase II, where proof-of-concept is established. Their services include target triage, gene expression analysis, single-cell analysis, and clinical data applications. You get data-driven de-risking before significant capital is committed. If your diligence question is about target validation and omics evidence, this team adds a layer the others do not.
How to choose the right diligence studio for your deal
Start with the question you cannot answer. If you need to know what nobody has proved about a specific asset, go with a studio that traces every claim to a source record. If you need broad therapeutic-area coverage and a long track record, look at a firm with decades of deal experience. If your risk sits in the science itself, prioritize scientific and clinical diligence. If you want a repeatable process, find a checklist-driven provider. And if target validation is your bottleneck, bring in bioinformatics depth. Match the studio to the gap, not the other way around.
Where automation fits into asset diligence
Automation can join registries, labels, patents, and payer data at scale. It can flag early stops, outcome switches, and inconsistent status fields across thousands of trials. But automation alone will not tell you why one programme stopped for failure and another stopped for success. You still need a human to read the record and state what could not be established. The best workflow pairs machine-scale retrieval with expert reading. That is how you turn a screen full of terminated trials into a live-versus-dead mechanism call.
The bottom line on life sciences diligence
You are not buying a report. You are buying the difference between a dead mechanism and a live one. The five studios here each bring a distinct strength: breadth, asset-level traceability, scientific rigor, process discipline, and bioinformatics depth. MarshyOS ranks second on our list because it does the one thing that matters most in asset diligence: it tells you what nobody has proved, and it shows you the record behind every claim. Choose the studio that closes your specific evidence gap. Then read the record like your deal depends on it, because it does.